Identification of bioactive natural products by pharmacophore-based virtual screening

Current Pharmaceutical Design

Volumn 16, Issue 15, 2010, Pages 1666-1681

  Schuster, Daniela ^a,b   Wolber, Gerhard ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b Inte:Ligand GmbH   (Austria)

Author keywords

Natural product databases; Natural products; Parallel screening; Pharmacophore modeling; Virtual screening

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; 7 OXOCHOLESTEROL; ABIETIC ACID; ARACHIDONATE 5 LIPOXYGENASE; CHALCONE; COAT PROTEIN; CORTISONE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOPAMINE; DOCEBENONE; FLAVANONE; FLURBIPROFEN; GALANTAMINE; GLYCYRRHETINIC ACID; HERBACEOUS AGENT; ISOFLAVONE; NATURAL PRODUCT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHYSOSTIGMINE; PLECONARIL; PREGNANE X RECEPTOR; RAGAGLITAZAR; ROSIGLITAZONE; SCOPOLETIN; SIGMA OPIATE RECEPTOR; SOLANIDINE; SOLASODINE; TESAGLITAZAR; UNINDEXED DRUG; BIOLOGICAL PRODUCT; DRUG;

ALZHEIMER DISEASE; CHINESE MEDICINE; CICHORIUM; COMPUTER MODEL; DATA BASE; DRUG CONFORMATION; DRUG SCREENING; HUMAN; HYDROGEN BOND; MEDICAL LITERATURE; MOLECULAR MODEL; NONHUMAN; PHARMACOGNOSY; PHARMACOPHORE; PRIORITY JOURNAL; QUORUM SENSING; REVIEW; RUTACEAE; SCOPOLIA; THEORETICAL MODEL; THEORY VALIDATION; X RAY CRYSTALLOGRAPHY; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; METHODOLOGY; STRUCTURE ACTIVITY RELATION;

BIOLOGICAL PRODUCTS; DRUG DISCOVERY; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; PHARMACOGNOSY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78049522482     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161210791164072     Document Type: Review

References (113)

1. Drews J. Drug discovery: a historical perspective. Science 2000; 287: 1960-4.
2. Butler MS. The role of natural product chemistry in drug discovery. J Nat Prod 2004; 67: 2141-53.
3. Saklani A, Kutty SK. Plant-derived compounds in clinical trials. Drug Discov Today 2008; 13: 161-71.
4. Rouhi AM. Rediscovering natural products. Chem Eng News 2003; 81: 77-91.
5. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007; 70: 461-77.
6. Li JW-H, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science 2009; 325: 161-5.
7. Newman DJ. Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J Med Chem 2008; 51: 2589-99.
8. Ehrlich P. Über den jetzigen Stand der Chemotherapie. Chem Ber 1909; 42: 17.
9. Wermuth CG. Glossary of terms used in medicinal chemistry (IUPAC recommendations 1998). Pure Appl Chem 1998; 70: 1129-43.
10. F. Molecular modeling and computer aided drug design. Examples of their applications in medicinal chemistry. Curr Med Chem 2000; 7: 141-58.
11. Greene J, Kahn SD, Savoj H, Sprague P, Teig SL. Chemical function queries for 3D database search. J Chem Inf Comput Sci 1994; 34: 1297-308.
12. Wolber G, Seidel T, Bendix F, Langer T. Molecule-pharmacophore superpositioning and pattern matching in computational drug design. Drug Discov Today 2008; 13: 23-9.
13. Gasteiger J. Of molecules and humans. J Med Chem 2006; 49: 6429-34.
14. Günther S, Senger C, Michalsky E, Goede A, Preissner R. Representation of target-bound drugs by computed conformers: implications for conformational libraries. BMC Bioinformatics 2006; 7: 293-304.
15. Brameld KA, Kuhn B, Reuter DC, Stahl M. Small molecule conformational preferences derived from crystal structure data. A medicinal chemistry focused analysis. J Chem Inf Model 2008; 48: 1-24.
16. Omega 2.0. www.eyesopen.com/products/applications/omega.html
17. ROTATE. www.molecular-networks.com/software/rotate/index.html
18. ConFirm. Accelrys Software Inc.: San Diego, CA, USA, 2003.
19. Li J, Ehlers T, Sutter J, Varma-O'Brien S, Kirchmair J. CAESAR: a new conformer generation algorithm based on recursive buildup and local rotational symmetry consideration. J Chem Inf Model 2007; 47: 1923-32.
20. DiscoveryStudio. Accelrys Inc.: San Diego, CA, 2007.
21. Boström J. Reproducing the conformations of protein-bound ligands: a critical evaluation of several popular conformational searching tools. J Comput Aided Mol Des 2001; 15: 1137-52.
22. Kirchmair J, Laggner C, Wolber G, Langer T. Comparative analysis of protein-bound ligand conformations with respect to Catalyst's conformational space subsampling algorithms. J Chem Inf Model 2005; 45: 422-30.
23. Boström J, Greenwood JR, Gottfries J. Assessing the performance of OMEGA with respect to retrieving bioactive conformations. J Mol Graph Model 2003; 21: 449-62.
24. Kirchmair J, Wolber G, Laggner C, Langer T. Comparative performance assessment of the conformational model generators Omega and Catalyst: a large-scale surveyon the retrieval of protein-bound ligand conformations. J Chem Inf Model 2006; 46: 1848-61.
25. Berman HM, Westbrook J, Feng Z, Gililand G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic Acids Res 2000; 28: 235-42.
26. Kirchmair J, Markt P, Distinto S, Schuster D, Spitzer GM, Liedl KR, et al. The protein data bank (PDB), its related services and software tools as key components for in silico guided drug discovery. J Med Chem 2008; 51: 7021-40.
27. Sayle R. Daylight User Group Meeting. Santa Fe, NM, USA, 2001.
28. Wolber G, Langer T. CombiGen: a novel software package for the rapid generation of virtual combinatorial libraries. Rational approaches to drug design. Proceedings of the 13. European Symposium on Quantitative Structure-Activity Relationships. Duesseldorf, Germany 2000; pp. 390-9.
29. Wolber G, Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 2005; 45: 160-9.
30. Steindl TM, Crump CE, Hayden FG, Langer T. Pharmacophore modelling, docking, and principal component analysis-based clustering: combined computer-assisted approaches to identify new inhibitors of the human rhino virus coat protein. J Med Chem 2005; 48: 6250-60.
31. Schuster D, Nashev LG, Kirchmair J, Laggner C, Wolber G, Langer T, et al. Discovery of non-steroidal 17β-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem 2008; 51: 4188-99.
32. Markt P, Schuster D, Kirchmair J, Laggner C, Langer T. Pharmacophore modeling and parallel screening for PPAR ligands. J Comput Aided Mol Des 2007; 21: 575-90.
33. Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001; 58: 737-47.
34. Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA. PHASE: A new design for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 2006; 20: 647-71.
35. Cottrell SJ, Gillet VJ, Taylor R. Incorporating partial matches within multiobjective pharmacophore identification. J Comput Aided Mol Des 2006; 20: 735-49.
36. Wolber G, Dornhofer AA, Langer T. Efficient overlay of small organic molecules using 3D pharmacophores. J Comput Aided Mol Des 2006; 20: 773-88.
37. Bolton EE, Wang Y, Thiessen PA, Bryant SH. PubChem: integrated platform of small molecules and biological activities. Ann Rep Comput Chem 2008; 4: 217-41.
38. Huang N, Shoichet BK, Irwin JJ. Benchmarking sets for molecular docking. J Med Chem 2006; 49: 6789-801.
39. Rohrer SG, Baumann K. Maximum unbiased validation (MUV) data sets for virtual screening based on PubChem bioactivity data. J Chem Inf Model 2009; 49: 169-84.
40. Langer T, Hoffmann RD. Pharmacophores and pharmacophore searches. Weinheim: Wiley-VCH 2006; p. 395.
41. Güner O. Pharmacophore perception, development, and use in drug design. La Jolla, CA: International University Line 2000; p. 560.
42. Jacobsson M, Liden P, Stjernschantz E, Bostroem H, Norinder U. Improving structure-based virtual screening by multivariate analysis of scoring data. J Med Chem 2003; 46: 5781-9.
43. Diller DJ, Li R. Kinases, homology models, and high throughput docking. J Med Chem 2003; 46: 4638-47.
44. Triballeau N, Acher F, Brabet I, Pin JP, Bertrand HO. Virtual screening workflow development guided by the receiver operating characteristic curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. J Med Chem 2005; 48: 2534-47.
45. Walters WP, Stahl MT, Murcko MA. Virtual screening - an overview. Drug Discov Today 1998; 3: 160-78.
46. Doman TN, McGovern SL, Witherbee BJ, Kasten TP, Kurumbail R, Stallings WC, et al. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J Med Chem 2002; 45: 2213-21.
47. Schuster D, Maurer E, Laggner C, Nashev LG, Wilckens T, Langer T, et al. The discovery of new 11 p-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening. J Med Chem 2006; 49: 3454-66.
48. Schuster D, Palusczak A, Hartmann RW, Langer T. Pharmacophore modeling and in silico screening for cytochrome P450 19 (aromatase) inhibitors. J Chem Inf Model 2006; 46: 1301-11.
49. Rella M, Rushworth CA, Guy JL, Turner AJ, Langer T, Jackson RM. Structure-based pharmacophore design and virtual screening for novel angiotensin converting enzyme 2 inhibitors. J Chem Inf Model 2006; 46: 708-16.
50. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997; 23: 3-25.
51. Oprea TI, Davis AM, Teague SJ, Leeson PD. Is there a difference between leads and drugs? A historical perspective. J Chem Inf Comput Sci 2001; 41: 1308-15.
52. Rishton GM. Reactive compounds and in vitro false positives in HTS. Drug Discov Today 1997; 2: 382-4.
53. Rishton GM. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov Today 2002; 8: 86-96.
54. Muegge I. Selection criteria for drug-like compounds. Med Res Rev 2003; 23: 302-21.
55. Choong NW, Cohen EEW. Forthcoming receptor tyrosine kinase inhibitors. Exp Opin Ther Targets 2006; 10: 793-7.
56. Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006; 33: 407-20.
57. Zimmermann GR, Lehár J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007; 12: 34-42.
58. Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br J Pharmacol 2007; 152: 9-20.
59. Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: applications to targets and beyond. Br J Pharmacol 2007; 152: 21-37.
60. Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, et al. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics 1999; 9: 477-89.
61. Ekins S, Bravi G, Wikel JH, Wrighton SA. Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther 1999; 291: 424-33.
62. Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, et al. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. Drug Metab Dis 2000; 28: 994-1002.
63. Ekins S, De Groot MJ, Jones JP. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab Dispos 2001; 29: 936-44.
64. Klabunde T, Evers A. GPCR antitarget modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects. ChemBioChem 2005; 6: 876-89.
65. Ekins S, Crumb WJ, Sarazan RD, Wikel JH, Wrighton SA. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J Pharmacol Exp Ther 2002; 301: 427-34.
66. Schuster D, Langer T. The identification of ligand features essential for PXR activation by pharmacophore modeling. J Chem Inf Model 2005; 45: 431-9.
67. Ekins S, Erickson JA. A pharmacophore for human pregnane X receptor ligands. Drug Metab Dis 2002; 30: 96-9.
68. Rollinger JM, Haupt S, Stuppner H, Langer T. Combining ethnopharmacology and virtual screening for lead structure discovery: COX-inhibitors as application example. J Chem Inf Comput Sci 2004; 44: 480-8.
69. Rollinger JM, Stuppner H, Langer T. In: Petersen F, Amstutz R, Eds. Natural compounds as drugs. Basel: Birkhäuser Verlag 2008; vol. I: pp. 213-49.
70. Steindl TM, Schuster D, Laggner C, Langer T. Parallel screening: a novel concept in pharmacophore modeling and virtual screening. J Chem Inf Model 2006; 46: 2146-57.
71. Steindl T, Schuster D, Laggner C, Chuang K, Hoffmann R, Langer T. Parallel screening and acitivity profiling with HIV protease inhibitor pharmacophore models. J Chem Inf Model 2007; 47: 563-71.
72. Füllbeck M, Michalsky E, Dunkel M, Preissner R. Natural products: sources and databases. Nat Prod Rep 2006; 23: 347-56.
73. AnalytiCon. www.ac-discovery.com/
74. BioFocus DPI natural product database. www.biofocusdpi.com/offerings/compound-libraries/natural-product.htm
75. Greenpharma natural compound library - GPN. www.greenpharma.com/html/products/product1.htm
76. InterbioScreen natural compound library. www.ibscreen.com/natural.shtml
77. Specs natural products. www.specs.net/page.php?pageid=2004120616213839&smenu=200811141113302 3
78. TimTec natural compound library. www.timtec.net/natural-compound-library.html
79. Tulip. vitasml.centro.ru
80. Franke L, Schwarz O, Müller-Kuhrt L, Hoernig C, Fische L, George S, et al. Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem 2007; 50: 2640-6.
81. Tanrikulu Y, Rau O, Schwarz O, Proschak E, Siems K, Müller-Kuhrt L, et al. Structure-based pharmacophore screeening for natural product-derived PPARy agonists. ChemBioChem 2009; 10: 75-8.
82. Buckingham J, Ed. Dictionary of natural products on DVD. Boca Raton, FL: CRC Press 2007; CD-ROM.
83. Rollinger JM, Steindl TM, Schuster D, Kirchmair J, Anrain K, Ellmerer EP, et al. Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. J Med Chem 2008; 51: 842-51.
84. S. Scientific reflections on traditional medicines in Austria; Master Thesis, Vienna: University of Vienna 2007; p. 381.
85. Fakhrudin N, Ladurner A, Heiss EH, Kramer M, Baumgartner L, Joa H, et al. Computer-aided discovery and mechanistical characterisation of natural neolignan compounds as novel PPARgamma agonists. Mol Pharmacol 2010; 77: e-pub ahead of print; doi: 10.1124/mol. 109.062141.
86. Wang SQ, Du QS, Zhao K, Li AX, Wei DQ, Chou KC. Virtual screening for finding natural inhibitor against cathepsin-L for SARS therapy. Amino Acids 2007; 33: 129-35.
87. nd ed. Hoboken, NJ: Wiley & Sons 2003; (CD-ROM).
88. Ehrman TM, Barlow DJ, Hylands PJ. Phytochemical databases of Chinese herbal constituents and bioactive plant compounds with known target specificities. J Chem Inf Model 2007; 47: 254-63.
89. Lei J, Zhou J. A marine natural products database. J Chem Inf Comput Sci 2002; 42: 742-8.
90. Derwent Chemical Information Systems, Inc.: Aliso Viejo, CA, 2005.
91. NCI open database. cactus.nci.nih.gov/ncidb2/download.html
92. Rollinger JM, Schuster D, Danzl B, Schwaiger S, Markt P, Schmidtke M, et al. In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens. Planta Med 2009; 75: 195-204.
93. Rollinger JM, Bodensieck A, Seger C, Ellmerer EP, Bauer R, Langer T, et al. Discovering COX-inhibiting constituents of Morus root bark: activity-guided versus computer-aided methods. Planta Med 2005; 71: 399-405.
94. Rollinger JM, Mock P, Zidorn C, Ellmerer EP, Langer T, Stuppner H. Application of the in combo screening approach for the discovery of non-alkaloid acetylcholinesterase inhibitors from Cichorium intybus. Curr Drug Discov Technol 2005; 2: 185-93.
95. Schuster D, Waltenberger B, Kirchmair J, Distinto S, Markt P, Stuppner H, et al. Predicting cyclooxygenase activity by three-dimensional pharmacophoric profiling. Part I: model generation, validation and applicability in ethnopharmacology. Mol Inf 2010; 29: 75-86.
96. Ertl P, Schuffenhauer A. Natural compounds as drugs. In: Petersen F, Amstutz R, Eds. Basel: Birkhäuser 2008; vol. II: pp. 217-35.
97. Ertl P, Roggo S, Schuffenhauer A. Natural product-likeness score and its application for prioritization of compound libraries. J Chem Inf Model 2008; 48: 68-74.
98. Cryer B, Feldmann M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 413-21.
99. Yoshimoto T, Yokoyama C, Ochi K, Yamamoto S, Maki Y, Ashida Y, et al. 2,3,5-Trimethyl-6-(12-hydroxy-5,10-dodeca-diynyl)-1,4-benzoquinone (AA861), a selective inhibitor of the 5-lipoxygenase reaction and the biosynthesis of slow-reacting substance of anaphylaxis. Biochim Biophys Acta 1982; 713: 470-3.
100. Rollinger JM, Hornick A, Langer T, Stuppner H, Prast H. Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products. J Med Chem 2004; 47: 6248-54.
101. Hashimoto K, Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and radiopharmaceuticals. Curr Pharm Des 2006; 12: 3857-76.
102. Laggner C, Schieferer C, Fiechtner B, Poles G, Hoffmann RD, Glossmann H, et al. Discovery of high-affinity ligands of sigma1 receptors, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening. J Med Chem 2005; 48: 4754-64.
103. Schweizer RA, Atanasov AG, Frey BM, Odermatt A. A rapid screening assay for inhibitors of 11 p-hydroxysteroid dehydrogenases (11p-HSD): flavanone selectively inhibits 11p-HSD1 reductase activity. Mol Cell Endocrinol 2003; 212: 41-9.
104. Monder C, Stewart PM, Lakshmi V, Valentino R, Burt D, Edwards CR. Licorice inhibits corticosteroid 11 beta-dehydrogenase of rat kidney and liver: in vivo and in vitro studies. Endocrinology 1989; 125: 1046-53.
105. Atanasov AG, Dzyakanchuk AA, Schweizer RAS, Nashev LG, Maurer E, Odermatt A. Coffee inhibits the reactivation of glucocorticoids by 11 p-hydroxysteroid dehydrogenase type 1: a glucocorticoid connection in the anti-diabetic action of coffee? FEBS Lett 2006; 580: 4081-5.
106. Gumy C, Thurnbichler C, Aubry EM, Balazs Z, Pfisterer P, Baumgartner L, et al. Inhibition of 11 p-hydroxysteroid dehydrogenase type 1 by plant extracts used as traditional antidiabetic medicines. Fitoterapia 2009; 80: 200-5.
107. Odermatt A, Atanasov AG, Balazs Z, Schweizer RA, Nashev LG, Schuster D, et al. Why is 11 p-hydroxysteroid dehydrogenase type 1 facing the endoplasmic reticulum lumen? Physiological relevance of the membrane topology of 11p-HSD1. Mol Cell Endocrinol 2006; 248: 15-30.
108. Wamil M, Andrew R, Chapman KE, Street J, Morton NM, Seckl JR. 7-Oxysterols modulate glucocorticoid acitivity in adipocytes through competition for 11 p-hydroxysteroid dehydrogenase type 1. Endocrinology 2008; 149: 5909-18.
109. Kiran MD, Adikesavan NV, Cirioni O, Giacometti A, Silvestri C, Scalise G, et al. Discovery of a quorum-sensing inhibitor of drug-resistant Staphylococcal infections by structure-based virtual screening. Mol Pharmacol 2008; 73: 1578-86.
110. Markt P, Petersen RK, Flindt EN, Kristiansen K, Kirchmair J, Spitzer G, et al. Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening. J Med Chem 2008; 51: 6303-17.
111. Lee JY, Jeong KW, Lee JU, Kang DI, Kim Y. Novel E. coli p-ketoacyl-acyl carrier protein synthase III inhibitors as targeted antibiotics. Bioorg Med Chem 2009; 17: 1506-13.
112. Purushottamachar P, Khandelwal A, Chopra P, Maheshwari N, Gediya LK, Vasaitis TS, et al. First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents. Bioorg Med Chem 2007; 15: 3413-21.
113. Rollinger JM. Accessing target information by virtual parallel screening - the impact on natural product research. Phytochem Lett 2009; 2: 53-8.